MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
First Claim
Patent Images
1. An isolated polynucleotide comprising;
- (a) a first region of linked nucleosides, said first region encoding a polypeptide of interest, said polypeptide of interest selected from the group consisting of SEQ ID NOs 35608-71005;
(b) a first flanking region located at the 5′
terminus of said first region comprising;
(i) a sequence of linked nucleosides selected from the group consisting of the native 5′
UTR of any of the nucleic acids that encode any of SEQ ID NOs 35608-71005, SEQ ID NOs;
1-4 and functional variants thereof; and
(ii) at least one 5′
terminal cap;
(c) a second flanking region located at the 3′
terminus of said first region comprising;
(i′
) a sequence of linked nucleosides selected from the group consisting of the native 3′
UTR of any of the nucleic acids that encode any of SEQ ID NOs 35608-71005, SEQ ID NOs 5-21 and functional variants thereof; and
(ii′
) a 3′
tailing sequence of linked nucleosides.
8 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
-
Citations
92 Claims
-
1. An isolated polynucleotide comprising;
-
(a) a first region of linked nucleosides, said first region encoding a polypeptide of interest, said polypeptide of interest selected from the group consisting of SEQ ID NOs 35608-71005; (b) a first flanking region located at the 5′
terminus of said first region comprising;(i) a sequence of linked nucleosides selected from the group consisting of the native 5′
UTR of any of the nucleic acids that encode any of SEQ ID NOs 35608-71005, SEQ ID NOs;
1-4 and functional variants thereof; and(ii) at least one 5′
terminal cap;(c) a second flanking region located at the 3′
terminus of said first region comprising;(i′
) a sequence of linked nucleosides selected from the group consisting of the native 3′
UTR of any of the nucleic acids that encode any of SEQ ID NOs 35608-71005, SEQ ID NOs 5-21 and functional variants thereof; and(ii′
) a 3′
tailing sequence of linked nucleosides. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 84, 86, 88, 90)
-
2. The isolated polynucleotide of claim 1 wherein the first region of linked nucleosides comprises at least an open reading frame of a nucleic acid sequence, wherein the nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 35554-35607 and 71006-251418.
-
3. The isolated polynucleotide of claim 1, wherein the 3′
- tailing sequence of linked nucleosides is selected from the group consisting of a poly-A tail of approximately 160 nucleotides and a polyA-G quartet.
-
4. The isolated polynucleotide of any one of claims 1-3 which is purified.
-
5. The isolated polynucleotide of any one of claims 1-4, wherein the at least one 5′
- terminal cap is selected from the group consisting of Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′
fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.
- terminal cap is selected from the group consisting of Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′
-
6. The isolated polynucleotide of any preceding claim, wherein at least one of said linked nucleosides comprises at least one modification as compared to the chemical structure of an A, G, U or C ribonucleotide.
-
7. The isolated polynucleotide of claim 6, wherein at least one said modification is located in a nucleoside base and/or sugar portion.
-
8. The isolated polynucleotide of any one of claims 1-7, wherein said first region comprises n number of linked nucleosides having Formula (Ia):
-
9. The isolated polynucleotide of claim 8, wherein B is not pseudouridine (ψ
- ) or 5-methyl-cytidine (m5C).
-
10. The isolated polynucleotide of any one of claims 8-9, wherein
U is O or C(RU)nu, wherein nu is an integer from 1 to 2 and each RU is, independently, H, halo, or optionally substituted alkyl; -
each of R1, R1′
, R1″
, R2, R2′
, and R2″
, if present, is independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, or optionally substituted aminoalkyl;each of R3 and R4 is, independently, H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxyalkoxy; each of Y1, Y2, and Y3, is, independently, O, S, —
NRN1—
, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;each Y4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, or optionally substituted amino; each Y5 is, independently, O or optionally substituted alkylene; and n is an integer from 10 to 10,000.
-
-
11. The isolated polynucleotide of claim 10, wherein each of R1, R1′
- , and R1″
, if present, is H.
- , and R1″
-
12. The isolated polynucleotide of claim 11, wherein each of R2, R2′
- , and R2″
, if present, is, independently, H, halo, hydroxy, optionally substituted alkoxy, or optionally substituted alkoxyalkoxy.
- , and R2″
-
13. The isolated polynucleotide of claim 10, wherein each of R2, R2′
- , and R2″
, if present, is H.
- , and R2″
-
14. The isolated polynucleotide of claim 13, wherein each of R1, R1′
- , and R1″
, if present, is, independently, H, halo, hydroxy, optionally substituted alkoxy, or optionally substituted alkoxyalkoxy.
- , and R1″
-
15. The isolated polynucleotide of claim 8, wherein said first region comprises n number of linked nucleotides having Formula (IIa):
-
16. isolated The polypeptide of claim 15, wherein said first region comprises n number of linked nucleosides having Formula (IIb) or (IIc), or a pharmaceutically acceptable salt thereof.
-
17. The isolated polynucleotide of claim 8, wherein said first region comprises n number of linked nucleosides having Formula (IId):
-
18. The isolated polypeptide of claim 17, wherein said first region comprises n number of linked nucleosides having Formula (IIe) or (IIf), or a pharmaceutically acceptable salt thereof.
-
19. The isolated polynucleotide of claim 8, wherein said first region comprises n number of linked nucleotides, each of said linked nucleotides independently having one of Formulas (IIg)-(IIj):
-
20. The isolated polynucleotide of claim 8, wherein said first region comprises n number of linked nucleosides having Formula (Ilk):
-
21. The isolated polynucleotide of claim 20, wherein said first region comprises n number of linked nucleosides having Formula (111):
-
22. The isolated polynucleotide of claim 20, wherein said first region comprises n number of linked nucleosides having Formula (IIm):
-
23. The isolated polynucleotide of any one of claims 11-22, wherein
U is O or C(RU)nu, wherein nu is an integer from 1 to 2 and each RU is, independently, H, halo, or optionally substituted alkyl; -
each of R1 and R2 is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, or optionally substituted aminoalkyl; each of R3 and R4 is, independently, H or optionally substituted alkyl; each of Y1, Y2, and Y3, is, independently, O, S, —
NRN1—
, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein RN1 is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;each Y4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, or optionally substituted amino; each Y5 is, independently, O or optionally substituted alkylene; and n is an integer from 10 to 10,000.
-
-
24. The isolated polynucleotide of claim 8, wherein said first region comprises n number of linked nucleosides having Formula (IIn):
-
25. The isolated polynucleotide of any one of claims 8-24, wherein in said n number of B has, each B independently has a formula selected from Formula (b1)-(b5):
-
26. The isolated polynucleotide of any one of claims 8-25, wherein n number of B has Formula (b6)-(b9):
-
27. The isolated polynucleotide of claim 26, wherein R12a, R12b, R12c, or RVa is substituted with —
- (CH2)s2(OCH2CH2)s1(CH2)s3OR′
, wherein s1 is an integer from 1 to 10, each of s2 and s3, independently, is an integer from 0 to 10, and R′
is H or C1-20 alkyl);
or —
NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10, each of s2 and s3, independently, is an integer from 0 to 10, and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl.
- (CH2)s2(OCH2CH2)s1(CH2)s3OR′
-
28. The isolated polynucleotide of any one of claims 8-27, wherein n number of B has Formula (b10)-(b14):
-
29. The isolated polynucleotide of any one of claims 7-27, wherein n number of B has Formula (b15)-(b17):
-
30. The polynucleotide of any one of claims 8-29, wherein n number of B has Formula (b18)-(b20):
-
31. The isolated polynucleotide of claim 30, wherein R26a, R26b, or R29 is substituted with —
- (CH2)s2(OCH2CH2)s1(CH2)s3OR′
, wherein s1 is an integer from 1 to 10, each of s2 and s3, independently, is an integer from 0 to 10, and R′
is H or C1-20 alkyl);
or —
NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10, each of s2 and s3, independently, is an integer from 0 to 10, and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl.
- (CH2)s2(OCH2CH2)s1(CH2)s3OR′
-
32. The isolated polynucleotide of any one of claims 8-31, wherein n number of B has Formula (b21):
-
33. The isolated polynucleotide of any one of claims 8-32, wherein n number of B has Formula (b22):
-
34. The isolated polynucleotide of any one of claims 8-33, wherein n number of B has Formula (b23):
-
35. The isolated polynucleotide of any one of claims 8-34, wherein n number of B has Formula (b24):
-
36. The isolated polynucleotide of any one of claims 1-35, further comprising a targeting moiety, wherein said targeting moiety is covalently bound to said polynucleotide.
-
37. The isolated polynucleotide of claim 36, wherein said targeting moiety is an antibody, thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, an RGD peptide, an RGD peptide mimetic, or an aptamer.
-
38. A pharmaceutical composition comprising the isolated polynucleotide of any one of claims 1-37.
-
39. A pharmaceutical composition comprising the isolated polynucleotide of any one of claims 1-37 and a pharmaceutically acceptable excipient.
-
40. The pharmaceutical composition of claim 39, wherein the excipient is selected from a solvent, aqueous solvent, non-aqueous solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, lipid, lipidoids liposome, lipid nanoparticle, core-shell nanoparticles, polymer, lipoplexe peptide, protein, cell, hyaluronidase, and mixtures thereof.
-
41. The pharmaceutical composition of claim 40, where the pharmaceutical composition comprises a lipid and wherein said lipid is selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DODMA, DSDMA, DLenDMA, reLNPs, PLGA and PEGylated lipids and mixtures thereof.
-
42. A method of producing a polypeptide of interest in a mammalian cell, tissue or organism comprising administering to said cell, tissue or organism the isolated polynucleotide of any one of claims 1-37 or the pharmaceutical composition of any of claims 38-41.
-
43. The method of claim 42, wherein the isolated polynucleotide is formulated.
-
44. The method of claim 43, wherein the formulation comprises a lipid which is selected from one of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DODMA, DSDMA, DLenDMA, reLNPs, PLGA, PEGylated lipids and mixtures or combinations thereof.
-
45. The method of claim 44, wherein the isolated polynucleotide is administered at a total daily dose of between 1 ug and 150 ug.
-
46. The method of claim 45, wheriein administration is by injection.
-
47. The method of claim 46, wherein administration is intradermal or subcutaneous or intramuscular or intravitreal.
-
48. The method of claim 45, wherein levels of the polypeptide of interest in the serum of the mammal are at least 50 pg/mL at least two hours after administration.
-
49. The method of claim 45, wherein the levels of the polypeptide of interest in the serum of the mammal remain above 50 pg/mL for at least 72 hours after administration.
-
50. The method of claim 49, wherein the levels of the polypeptide of interest in the serum of the mammal remain above 60 pg/mL for at least 72 hours after administration.
-
51. The method of claim 44, wherein the resulting polynucleotide formulation has a mean particle size of 80 nm-160 nm, a PDI of between 0.02 and 0.20 and a lipid to polnucleotide ratio (wt/wt) of between 10-20.
-
52. A method for producing an increased level of a polypeptide of interest selected from the group consisting of SEQ ID NOs 35608-71005 in a mammalian cell, tissue or organism, comprising administering to said cell, tissue or organism a total daily dose of the isolated polynucleotide of any one of claims 4-37 or the pharmaceutical composition of any one of claims 38-41 in two or more equal or unequal split doses.
-
53. The method of claim 52, wherein the level of the polypeptide produced in response to said administration is greater than the levels produced by administering the same total daily dose of the isolated polynucleotide or pharmaceutical composition as a single administration.
-
54. The method of claim 52, wherein the mammalian organism is a human patient in need of an increased level of the polypeptide of interest.
-
55. The method of claim 54, wherein the increased level of the polypeptide of interest is detectable in a bodily fluid of said patient.
-
56. The method of claim 55, wherein the bodily fluid is selected from the group consisting of peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper'"'"'s fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and umbilical cord blood.
-
57. The method of claim 56, wherein the bodily fluid is serum and the polpeptide per unit drug (PUD) is greater than 1.
-
58. The method of claim 57, wherein the dose splitting factor (DSF) is greater than 4.
-
59. The method of claim 55, wherein administration is transdermal.
-
60. The method of claim 59, wherein transdermal administration comprises utilization of one or more members selected from the group consisting of a patch, cream, ointment, mechanical device, needle, sponge, depot and fabric.
-
61. The method of claim 59, wherein administration is according to a dosing regimen which occurs over the course of hours, days, weeks, months, or years.
-
62. The method of claim 52, wherein said two or more split doses comprise a first dose of the polynucleotide or pharmaceutical composition administered at a time T1 followed by a second dose of the polynucleotide or pharmaceutical composition administered at a time T2, wherein said time T1 and said time T2 are separated by no more than 1 minute and wherein said first dose and said second dose are administered in amounts that result in higher levels of the polypeptide of interest in said subject than if the amounts of polynucleotide or pharmaceutical composition were administered together in a single unit dose.
-
63. The method of claim 62, further comprising administering a plurality of doses of said polynucleotide or pharmaceutical composition, Nx at times Tn, wherein x and n are independently selected from 3 to about 1000 and where the time between Tn and Tn+1 is separated by increments of no more than 10 seconds.
-
64. The method of claim 63, wherein administration occurs by direct injection.
-
65. The method of claim 64, wherein direct injection is selected from the group consisting of intravenous, intradermal, subcutaneous, intramuscular and intravitreal.
-
66. The method of claim 64, wherein said first dose is administered proximal to said second or plurality of doses.
-
67. The method of claim 64, wherein said first dose is administered distal to said second or plurality of doses.
-
68. The method of claim 64, wherein the distance between the site of injection of said first dose and the site of injection of any second or plurality of doses is from about 1 mm to about 10 cm.
-
69. The method of claim 64, wherein injection is made at a depth of from 0.1 mm to about 1 cm.
-
70. The method of claim 65, wherein direct injection is achieved by using one or more devices selected from multineedle injection systems, catheter or lumen systems, and ultrasound, electrical or radiation based systems.
-
71. The method of claim 63, wherein the amount polynucleotide or pharmaceutical composition administered in any dose is substantially equal.
-
72. The method of claim 63, wherein time T1 and time T2 are separated by no more than 30 seconds.
-
73. The method of claim 63, wherein time T1 and time T2 are separated by no more than 10 seconds.
-
74. The method of claim 63, wherein the first dose, the second dose and any of a plurality of doses are administered at substantially the same time.
-
75. The method of claim 63, wherein the single unit dose is between about 10 mg/kg and about 500 mg/kg.
-
76. The method of claim 63, wherein the single unit dose is between about 1.0 mg/kg and about 10 mg/kg.
-
77. The method of claim 63, wherein the single unit dose is between about 0.001 mg/kg and about 1.0 mg/kg.
-
84. The method of any of claims 78-83, wherein the polynucleotide is selected from the polynucleotide of any of claims 1-37.
-
86. A lipid nanopartical formulation of claim 85, wherein the polynucleotide is selected from the polynucleotide of any of claims 1-37.
-
88. A reLNP formulation of claim 87, wherein the polynucleotide is selected from the polynucleotide of any of claims 1-36.
-
90. A sustained release formulation of claim 89, wherein the polynucleotide is selected from the polynucleotide of any of claims 1-36.
-
2. The isolated polynucleotide of claim 1 wherein the first region of linked nucleosides comprises at least an open reading frame of a nucleic acid sequence, wherein the nucleic acid sequence selected from the group consisting of SEQ ID NOs:
-
-
78. A method of preparing a lipid nanopartical formulation of a polynucleotide encoding a polypeptide of interest comprising rapidly injecting a first ethanolic solution into a second aqueous solution wherein,
(a) said first ethanolic solution comprises a mixture of lipid: - DSPC;
Cholesterol;
PEG-c-DOMG to yield a molar ratio of 50;
10;
38.5;
1.5 and having a final lipid concentration of approximately 25 mM, and(b) said second aqueous solution comprises a sodium citrate buffered solution of the polynucleotide encoding the polypeptide of interest having a concentration of 1-2 mg/mL and a pH of approximately 3, wherein the rapid injection results in a suspension containing 33% ethanol and a total lipid to polynucleotide weight ratio of at least 10;
1.- View Dependent Claims (79, 80, 81, 82, 83, 85)
-
79. The method of claim 78, wherein the rapid injection is performed either manually (MI) or by the aid of a syringe pump (SP).
-
80. The method of claim 79, further comprising dialyzing the resultant suspension against phosphate buffered saline (PBS) at pH 7.4.
-
81. The method of claim 80, wherein dialysis is performed more than once.
-
82. The method of claim 81, further comprising filtering the dialyzed suspension through a 0.2 μ
- m sterile filter.
-
83. The method of any of claims 78-82, wherein the lipid is selected from the group consisting of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DODMA, DSDMA, DLenDMA, reLNPs, PLGA and PEGylated lipids.
-
85. A lipid nanopartical formulation of a polynucleotide encoding a polypeptide of interest produced by the method of any of claims 78-83 and having a particle size of 80 nm-160 nm, a PDI of between 0.02 and 0.20 and a lipid to polnucleotide ratio (wt/wt) of between 10-30.
- DSPC;
-
87. A reLNP formulation of a polynucleotide said polynucleotide encoding a polypeptide of interest.
-
89. A sustained release formulation of a polynucleotide said polynucleotide encoding a polypeptide of interest.
-
91. A polynucleotide encoding a fusion protein said fusion protein comprising a first polypeptide and a second polypeptide.
- View Dependent Claims (92)
-
92. The polynucleotide of claim 91 where the first polypeptide is selected from the group consisting of Fc receptor, Fab fragment, Fab′
- fragment, F(ab′
)2 fragment, Fv fragment, IgA domain, IgD domain, IgE domain, IgD domain, IgM domain, IgV domain, IgC1 domain, IgC2 domain and IgI domain and the second polypeptide is a polypeptide of interest.
- fragment, F(ab′
-
92. The polynucleotide of claim 91 where the first polypeptide is selected from the group consisting of Fc receptor, Fab fragment, Fab′
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeModerna Therapeutics, Inc. (Moderna, Inc.)
-
Original AssigneeModerna Therapeutics, Inc. (Moderna, Inc.)
-
InventorsBancel, Stephane, Chakraborty, Tirtha, de Fougerolles, Antonin, Elbashir, Sayda M., John, Matthias, Roy, Atanu, Whoriskey, Susan, Wood, Kristy M., Hatala, Paul, Schrum, Jason P., Ejebe, Kenechi, Ellsworth, Jeff Lynn, Guild, Justin
-
Application NumberUS13/791,910Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current424/450CPC Class CodesA61K 31/7115 Nucleic acids or oligonucle...A61K 38/00 Medicinal preparations cont...A61K 38/17 from animals; from humans e...A61K 38/177 Receptors; Cell surface ant...A61K 38/1816 Erythropoietin [EPO]A61K 38/1891 Angiogenesic factors; Angio...A61K 38/191 Tumor necrosis factors [TNF...A61K 38/193 Colony stimulating factors ...A61K 38/212 IFN-alphaA61K 38/45 Transferases (2)A61K 38/4846 Factor VII (3.4.21.21); Fac...A61K 47/543 Lipids, e.g. triglycerides;...A61K 48/0033 the non-active part being n...A61K 48/0041 the non-active part being p...A61K 48/005 characterised by an aspect ...A61K 48/0066 Manipulation of the nucleic...A61K 48/0075 characterised by an aspect ...A61K 9/0019 Injectable compositions; In...A61K 9/1271 Non-conventional liposomes,...A61K 9/145 with organic compoundsA61K 9/5123 : Organic compounds, e.g. fat...A61K 9/5146 : obtained otherwise than by ...A61K 9/5153 : Polyesters, e.g. poly(lacti...A61P 1/00 : Drugs for disorders of the ...A61P 1/04 : for ulcers, gastritis or re...A61P 11/00 : Drugs for disorders of the ...A61P 13/00 : Drugs for disorders of the ...A61P 13/12 : of the kidneysA61P 15/00 : Drugs for genital or sexual...A61P 17/00 : Drugs for dermatological di...A61P 17/02 : for treating wounds, ulcers...A61P 17/04 : AntipruriticsA61P 17/06 : AntipsoriaticsA61P 17/08 : AntiseborrheicsA61P 17/14 : for baldness or alopeciaA61P 19/00 : Drugs for skeletal disordersA61P 19/02 : for joint disorders, e.g. a...A61P 19/10 : for osteoporosisA61P 21/00 : Drugs for disorders of the ...A61P 21/04 : for myasthenia gravisA61P 25/00 : Drugs for disorders of the ...A61P 25/02 : for peripheral neuropathiesA61P 25/14 : for treating abnormal movem...A61P 25/18 : Antipsychotics, i.e. neurol...A61P 25/24 : AntidepressantsA61P 25/28 : for treating neurodegenerat...A61P 25/30 : for treating abuse or depen...A61P 27/02 : Ophthalmic agentsA61P 29/00 : Non-central analgesic, anti...A61P 3/00 : Drugs for disorders of the ...A61P 3/06 : AntihyperlipidemicsA61P 3/10 : for hyperglycaemia, e.g. an...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/10 : AntimycoticsA61P 31/12 : AntiviralsA61P 31/14 : for RNA virusesA61P 31/18 : for HIVA61P 35/00 : Antineoplastic agentsA61P 35/02 : specific for leukemiaA61P 35/04 : specific for metastasisA61P 37/00 : Drugs for immunological or ...A61P 37/02 : ImmunomodulatorsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 7/00 : Drugs for disorders of the ...A61P 7/02 : Antithrombotic agents; Anti...A61P 7/04 : Antihaemorrhagics; Procoagu...A61P 7/06 : AntianaemicsA61P 9/00 : Drugs for disorders of the ...A61P 9/10 : for treating ischaemic or a...C07H 21/02 : with ribosyl as saccharide ...C07K 14/005 : from virusesC07K 14/435 : from animals; from humansC07K 14/43595 : from coelenteratae, e.g. me...C07K 14/47 : from mammalsC07K 14/4705 : stimulating, promoting or a...C07K 14/4713 : Autoimmune diseases, e.g. I...C07K 14/4723 : Cationic antimicrobial pept...C07K 14/4746 : p53C07K 14/475 : Growth factors; Growth regu...C07K 14/485 : Epidermal growth factor [EG...C07K 14/495 : Transforming growth factor ...C07K 14/505 : Erythropoietin [EPO]C07K 14/515 : Angiogenesic factors; Angio...C07K 14/525 : Tumour necrosis factor [TNF]C07K 14/535 : Granulocyte CSF; Granulocyt...C07K 14/5418 : IL-7C07K 14/56 : IFN-alphaC07K 14/61 : Growth hormone [GH], i.e. s...C07K 14/62 : InsulinsC07K 14/705 : Receptors; Cell surface ant...C07K 14/745 : Blood coagulation or fibrin...C07K 16/00 : Immunoglobulins [IGs], e.g....C07K 16/2863 : against receptors for growt...C07K 16/2887 : against CD20C07K 16/40 : against enzymesC12N 15/11 : DNA or RNA fragments; Modif...C12N 15/52 : Genes encoding for enzymes ...C12N 15/85 : for animal cellsC12N 15/87 : Introduction of foreign gen...C12N 15/88 : using microencapsulation, e...C12N 9/0069 : acting on single donors wit...C12N 9/0091 : oxidizing metal ions (1.16)C12N 9/1051 : Hexosyltransferases (2.4.1)C12N 9/1241 : Nucleotidyltransferases (2....C12N 9/16 : acting on ester bonds (3.1)C12N 9/2402 : hydrolysing O- and S- glyco...C12N 9/2445 : Beta-glucosidase (3.2.1.21)C12N 9/6435 : Plasmin (3.4.21.7), i.e. fi...C12N 9/6437 : Coagulation factor VIIa (3....C12N 9/644 : Coagulation factor IXa (3.4...C12N 9/6443 : Coagulation factor XIa (3.4...C12N 9/6451 : Coagulation factor XIIa (3....C12N 9/88 : Lyases (4.)C12N 9/93 : Ligases (6)C12P 13/04 : Alpha- or beta- amino acids...C12P 21/00 : Preparation of peptides or ...C12P 21/005 : Glycopeptides, glycoproteinsC12Y 113/12007 : Photinus-luciferin 4-monoox...C12Y 116/03001 : Ferroxidase (1.16.3.1), i.e...C12Y 207/07012 : UDP-glucose--hexose-1-phosp...C12Y 304/21007 : Plasmin (3.4.21.7), i.e. fi...C12Y 304/21022 : Coagulation factor IXa (3.4...C12Y 304/21027 : Coagulation factor XIa (3.4...C12Y 403/02001 : Argininosuccinate lyase (4....C12Y 603/02019 : Ubiquitin-protein ligase (6...Y02A 50/30 : Against vector-borne diseas...